Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02273193 · ClinicalTrials.gov registry record

Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes

A clinical trial of Gestational Diabetes Mellitus, sponsored by Mike O'Callaghan Military Hospital.

Completed
Registry status
643
Enrollment target
1
Study location

NCT02273193 is a study of Gestational Diabetes Mellitus that has completed, run by Mike O'Callaghan Military Hospital. The registered enrollment target is 643 participants, above the 379-participant average among 16 other Gestational Diabetes Mellitus trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02273193, a study of Gestational Diabetes Mellitus, has completed, sponsored by Mike O'Callaghan Military Hospital.

COMPLETED
Registry status
643 participants
Enrollment target
1
Study location

Study Summary

A prospective cohort research study is being conducted in the Mike O'Callaghan Federal Medical Center (MOFMC), Department of Family Medicine, Obstetrics Clinic to determine if early screening with hemoglobin A1C, a blood test for blood glucose, can be used to identify women with hyperglycemia or Gestational Diabetes Mellitus (GDM) in the first semester of pregnancy in place of a fasting blood glucose blood test. This study will also determine how hemoglobin A1C compares with the oral glucose tolerance test (GTT) done as a standard of care with the standard of care second trimester prenatal care testing. Subjects recruited and consented during the Obstetrics Orientation Class will have two (2) additional blood tests drawn with their standard of care prenatal tests in the first trimester (\<13 weeks) of pregnancy and at the second trimester (24-28 weeks) of pregnancy. Subjects identified as having GDM by blood HbA1C, fasting glucose or the 2 hr OGTT will be treated for GDM with standard of care by their primary care provider. The correlation of blood HbA1C with the fasting glucose in the first trimester of pregnancy and with the 2 hr OGTT will be determined for early detection and diagnosis of GDM. This study will contribute to understanding the role of HbA1C in pregnancy and the development of GDM.

Study Locations (1)

Nevada

  • Mike O'Callaghan Federal Medical Center - Nellis Air Force Base

Trial Details

FieldValue
Enrollment Target 643 participants
Start Date 2014-10-14
Est. Completion 2017-07-01

Sponsor

Mike O'Callaghan Military Hospital

26 total trials

What the Registry Record Tells You About NCT02273193

The ClinicalTrials.gov registry entry for NCT02273193 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 379-participant average among 16 other Gestational Diabetes Mellitus trials with a reported enrollment target (70% higher). The listed sponsor is Mike O'Callaghan Military Hospital, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gestational Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.

NCT02273193 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT02273193 about?

NCT02273193 is a clinical study titled "Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes". A prospective cohort research study is being conducted in the Mike O'Callaghan Federal Medical Center (MOFMC), Department of Family Medicine, Obstetrics Clinic to determine if early screening with hemoglobin A1C, a blood test for blood glucose, can be used to identify women with hyperglycemia or Ges...

What is the current status of trial NCT02273193?

This trial is currently completed. The enrollment target is 643 participants. The study started on 2014-10-14. Estimated completion is 2017-07-01.

What conditions does trial NCT02273193 study?

This clinical trial studies the following conditions: Gestational Diabetes Mellitus.

Who is sponsoring clinical trial NCT02273193?

This trial is sponsored by Mike O'Callaghan Military Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02273193 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gestational Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.